Detailed Notes on M3541
The main end place was the protection and tolerability of sifalimumab. Treatment method-emergent adverse functions (AEs) and significant AEs (SAEs) and their severity, result, and any connection to the review medication were recorded because of the investigator all through the study. AEs have been considered prone to be connected to examine medicat